A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

Trial Profile

A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Alpelisib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 26 Sep 2017 Planned initiation date changed from 1 May 2017 to 1 Sep 2017.
    • 05 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top